Myelodysplastic syndromes, version 2.2015 Journal Article
| Authors: | Greenberg, P. L.; Stone, R. M.; Bejar, R.; Bennett, J. M.; Bloomfield, C. D.; Borate, U.; De Castro, C. M.; Deeg, H. J.; DeZern, A. E.; Fathi, A. T.; Frankfurt, O.; Gaensler, K.; Garcia-Manero, G.; Griffiths, E. A.; Head, D.; Klimek, V.; Komrokji, R.; Kujawski, L. A.; Maness, L. J.; O'Donnell, M. R.; Pollyea, D. A.; Scott, B.; Shami, P. J.; Stein, B. L.; Westervelt, P.; Wheeler, B.; Shead, D. A.; Smith, C. |
| Article Title: | Myelodysplastic syndromes, version 2.2015 |
| Abstract: | The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore a critical component of decision-making in the treatment of MDS. The development of newer treatments and the refinement of current treatment modalities are designed to improve patient outcomes and reduce side effects. These NCCN Guidelines Insights focus on the recent updates to the guidelines, which include the incorporation of a revised prognostic scoring system, addition of molecular abnormalities associated with MDS, and refinement of treatment options involving a discussion of cost of care. © JNCCN-Journal of the National Comprehensive Cancer Network. |
| Keywords: | gene mutation; review; medical decision making; practice guideline; cost effectiveness analysis; patient care; myelodysplastic syndrome; professional practice; clinical evaluation; human; prognostic assessment; international prognostic scoring system revised |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 13 |
| Issue: | 3 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2015-03-01 |
| Start Page: | 261 |
| End Page: | 272 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 25736003 |
| PMCID: | PMC4696005 |
| DOI/URL: | |
| Notes: | Export Date: 2 April 2015 -- Source: Scopus |
